A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

Author： Wong Nan Soon   Meadows Kellen L.   Rosen Lee S.   Adjei Alex A.   Kaufmann Scott H.   Morse Michael A.   Petros William P.   Zhu Yali   Statkevich Paul   Cutler David L.   Meyers Michael L.   Hurwitz Herbert I.  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.29, Iss.9, 2011-10, pp. : 617-625

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

By Awada A.   Eskens F.A.L.M.   Piccart M.   Cutler D.L.   van der Gaast A.   Bleiberg H.   Wanders J.   Faber M.N.   Statkevich P.   Fumoleau P.   Verweij J.   for the EORTC Early Clinical Studies Group  

European Journal of Cancer, Vol. 38, Iss. 17, 2002-11 ,pp. : 2272-2278

Elsevier

Access to resources Recommend Favorite

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

By Chow Laura   Eckhardt S.   O’Bryant Cindy   Schultz Mary   Morrow Mark   Grolnic Stacy   Basche Michele   Gore Lia  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 631-646

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

A Phase I Trial of Gemcitabine Administered as a 96-h Continuous Intravenous Infusion in Patients with Advanced Carcinoma and Lymphoma

By  

Medical Oncology, Vol. 23, Iss. 3, 2006-09 ,pp. : 369-376

Humana Press, Inc

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins v 3 and v 5 in patients with advanced solid tumours

By Eskens F.A.L.M.   Dumez H.   Hoekstra R.   Perschl A.   Brindley C.   Bottcher S.   Wynendaele W.   Drevs J.   Verweij J.   van Oosterom A.T.  

European Journal of Cancer, Vol. 39, Iss. 7, 2003-05 ,pp. : 917-926

Elsevier

Access to resources Recommend Favorite